<DOC>
	<DOC>NCT01101100</DOC>
	<brief_summary>This study is an open-label extension of study 20090062 to evaluate extended subcutaneous dosing of AMG 827 for up to 362 weeks.</brief_summary>
	<brief_title>Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject was randomized into Study 20090062 and completed the week 16 evaluation. Subject had any Serious Adverse Event (SAE) reported during Study 20090062 that was considered possibly related to IP. Subject experienced an adverse event in Study 20090062 that, in the opinion of the investigator, could cause extension of treatment to be detrimental to the subject.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>